14 Apr, 2020
SHANGHAI, China, April. 14, 2020 -- Genor Biopharma Co. Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing immune-oncology therapeutics, today announced that the preliminary clinical data on its investigational PD-1 inhibitor Geptanolimab would be presented at the 111st American Association for Cancer Research (AACR) Annual meeting. Among which the data on PTCL will be orally presented by Dr. Shi Yuankai at online annual meeting on April. 28 at the clinical trials plenary sessions.
1275
29 Jan, 2020
SHANGHAI, CHINA—Genor Biopharm, with all employees across 4 sites in China and the U.S., has announced to donate RMB500,000 to battle the outbreak of new coronavirus-related pneumonia in Hubei province, China. The donation will be immediately used to purchase medical consumables and support medical professionals in Hubei. Genor has been closely monitoring the situation and is ready to provide all necessary help to employees from impacted regions.
1274
19 Sep, 2019
SHANGHAI, CHINA--Genor Biopharma has announced the completion of the Phase I clinical trial of GB221 in HER2+ breast cancer patients. This randomized, multicenter, single-dose trial evaluated tolerance, safety, pharmacokinetic characteristics and immunogenicity of GB221. The results showed that GB221 was safe and had similar pharmacokinetic and immunogenicity characteristics to Herceptin.
1273
19 Sep, 2019
SHANGHAI, CHINA--Genor Biopharma has announced the completion of the Phase I clinical trial of GB221 in HER2+ breast cancer patients. This randomized, multicenter, single-dose trial evaluated tolerance, safety, pharmacokinetic characteristics and immunogenicity of GB221. The results showed that GB221 was safe and had similar pharmacokinetic and immunogenicity characteristics to Herceptin.
1255